RARE is trading 4.9% down at $27.35 as investors lock in gains following a sharp multi-day run-up in recent sessions.
- The pullback appears to be a technical position reset rather than a reaction to a specific Ultragenyx event, with no new filings, press releases, or analyst calls reported overnight.
- The move follows a period of significant strength across the broader biotech sector and risk assets.